ArticleiScience2024

Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma.

Ruizhi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.